Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs for Steroid-resistant Severe aGVHD
NCT03631589Phase 3Unknown
- Sponsor
- Fujian Medical University
- Start
- Dec 2017
- Primary completion
- Dec 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3 trial of mesenchymal stem cells in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Fujian Medical University. Primary endpoint: complete and partial response rate at 1 year. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03631589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631589.